Table 2.

Summary of TH-302 monotherapy, gemcitabine and nab-paclitaxel doublet, and gemcitabine, nab-paclitaxel and TH-302 triplet induced maximal body weight loss in the PDAC tumor bearing nu/nu and non-tumor bearing CD-1 immunocompetent mice

Cell Line	Hs766t	MIA PaCa-2	PANC-1	BxPC3	Non-tumor	Non-tumor
Mouse Strain	nu/nu	nu/nu	nu/nu	nu/nu	CD-1	CD-1
Sex	Female	Female	Female	Female	Female	Male
# of Animal/group	n = 10	n = 10	n = 10	n = 10	n = 6	n = 10
Vehicle	0	0	0	0	0	0
T	0	0	0	0	0	0
G + nP Doublet	13% (Day 15)	14.2% (Day 15)	11.1% (Day 15)	9% (Day 14)	4.2% (Day 11)	5.4% (Day 10)
G + nP + T Triplet	12.3% (Day 15)	13% (Day 15)	12.3% (Day 15)	8.2% (Day 11)	3% (Day 8)	1.7% (Day 14)